NYSE - Delayed Quote USD

Bio-Rad Laboratories, Inc. (BIO)

282.00 +4.69 (+1.69%)
At close: May 10 at 4:00 PM EDT
265.80 -16.20 (-5.74%)
After hours: May 10 at 6:10 PM EDT
Loading Chart for BIO
DELL
  • Previous Close 277.31
  • Open 279.06
  • Bid 282.33 x 3100
  • Ask 282.62 x 3000
  • Day's Range 277.79 - 286.01
  • 52 Week Range 261.59 - 431.79
  • Volume 230,324
  • Avg. Volume 218,738
  • Market Cap (intraday) 8.033B
  • Beta (5Y Monthly) 0.94
  • PE Ratio (TTM) --
  • EPS (TTM) -10.69
  • Earnings Date Aug 1, 2024 - Aug 5, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 377.80

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

www.bio-rad.com

8,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BIO

Performance Overview: BIO

Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BIO
12.66%
S&P 500
9.49%

1-Year Return

BIO
23.13%
S&P 500
26.79%

3-Year Return

BIO
53.62%
S&P 500
23.39%

5-Year Return

BIO
8.82%
S&P 500
81.93%

Compare To: BIO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIO

Valuation Measures

Annual
As of 5/10/2024
  • Market Cap

    8.03B

  • Enterprise Value

    7.79B

  • Trailing P/E

    --

  • Forward P/E

    25.91

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.13

  • Price/Book (mrq)

    0.89

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -12.37%

  • Return on Assets (ttm)

    1.62%

  • Return on Equity (ttm)

    -3.43%

  • Revenue (ttm)

    2.61B

  • Net Income Avi to Common (ttm)

    -322.37M

  • Diluted EPS (ttm)

    -10.69

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.65B

  • Total Debt/Equity (mrq)

    13.26%

  • Levered Free Cash Flow (ttm)

    209.61M

Research Analysis: BIO

Company Insights: BIO

Research Reports: BIO

People Also Watch